Arbaz A Momin1,2, Miguel A Recinos3, Gino Cioffi4,5,6, Nirav Patil6,7, Pranay Soni2,3, João Paulo Almeida2,3, Carol Kruchko6, Jill S Barnholtz-Sloan4,5,6,7,8, Pablo F Recinos1,2,3, Varun R Kshettry9,10,11. 1. Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA. 2. Department of Neurological Surgery, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA. 3. Rose Ella Burkhardt Brain Tumor & Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA. 4. Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA. 5. Cleveland Center for Health Outcomes Research (CCHOR), Cleveland, OH, USA. 6. Central Brain Tumor Registry of the United States, Hinsdale, IL, USA. 7. University Hospitals Research and Education Institute, Cleveland, OH, USA. 8. Case Comprehensive Cancer Center, Cleveland, OH, USA. 9. Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA. kshettv@ccf.org. 10. Department of Neurological Surgery, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA. kshettv@ccf.org. 11. Rose Ella Burkhardt Brain Tumor & Neuro-Oncology Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA. kshettv@ccf.org.
Abstract
PURPOSE: Craniopharyngiomas are rare benign brain tumors originating from errors in differentiation during embryogenesis. Given current interest in treatments that target genetic and molecular signatures of specific craniopharyngioma subtypes, updated and comprehensive epidemiologic data of these subtypes are necessary to inform and direct resources. METHODS: We utilized data from the Central Brain Tumor Registry of the United States (CBTRUS), which represents 100% of the US population. Incidence by demographics was calculated only for histologically-confirmed cases. Age-adjusted annual incidence was calculated and is reported per 100,000 persons. Annual percent change (APC) in incidence rates from 2004 to 2016 was calculated to assess trends. RESULTS: From 2004 to 2016, 7441 craniopharyngiomas were diagnosed in the United States, representing approximately 620 new cases each year. The incidence for histologically-confirmed cases was 0.16 per 100,000 persons. The age distribution was bimodal, with one peak in 5- to 9-year-olds and another in 55- to 69-year-olds. Compared with adamantinomatous tumors, papillary craniopharyngiomas only represented 5.5% of the histologically diagnosed craniopharyngiomas in 0- to 29-year-olds, 30.6% in 30- to 59-year-olds, and 30.4% in 60 + year-olds. Incidence was highest amongst Blacks (0.22), followed by Whites (0.15), Asians or Pacific Islanders (0.14), and American Indians/Alaska Natives (0.10). No significant difference was discovered in incidence rates between males and females or Hispanic and non-Hispanic ethnicities. CONCLUSIONS: Craniopharyngiomas are rare tumors with a bimodal age distribution and an equal male-to-female incidence. Black patients had the highest incidence, and adamantinomatous craniopharyngiomas were significantly more common than papillary tumors in adolescent, adult, and elderly populations.
PURPOSE: Craniopharyngiomas are rare benign brain tumors originating from errors in differentiation during embryogenesis. Given current interest in treatments that target genetic and molecular signatures of specific craniopharyngioma subtypes, updated and comprehensive epidemiologic data of these subtypes are necessary to inform and direct resources. METHODS: We utilized data from the Central Brain Tumor Registry of the United States (CBTRUS), which represents 100% of the US population. Incidence by demographics was calculated only for histologically-confirmed cases. Age-adjusted annual incidence was calculated and is reported per 100,000 persons. Annual percent change (APC) in incidence rates from 2004 to 2016 was calculated to assess trends. RESULTS: From 2004 to 2016, 7441 craniopharyngiomas were diagnosed in the United States, representing approximately 620 new cases each year. The incidence for histologically-confirmed cases was 0.16 per 100,000 persons. The age distribution was bimodal, with one peak in 5- to 9-year-olds and another in 55- to 69-year-olds. Compared with adamantinomatous tumors, papillary craniopharyngiomas only represented 5.5% of the histologically diagnosed craniopharyngiomas in 0- to 29-year-olds, 30.6% in 30- to 59-year-olds, and 30.4% in 60 + year-olds. Incidence was highest amongst Blacks (0.22), followed by Whites (0.15), Asians or Pacific Islanders (0.14), and American Indians/Alaska Natives (0.10). No significant difference was discovered in incidence rates between males and females or Hispanic and non-Hispanic ethnicities. CONCLUSIONS: Craniopharyngiomas are rare tumors with a bimodal age distribution and an equal male-to-female incidence. Black patients had the highest incidence, and adamantinomatous craniopharyngiomas were significantly more common than papillary tumors in adolescent, adult, and elderly populations.
Authors: Saksham Gupta; Wenya Linda Bi; Alexandra Giantini Larsen; Sally Al-Abdulmohsen; Malak Abedalthagafi; Ian F Dunn Journal: Neurosurg Focus Date: 2018-06 Impact factor: 4.047
Authors: Brad E Zacharia; Samuel S Bruce; Hannah Goldstein; Hani R Malone; Alfred I Neugut; Jeffrey N Bruce Journal: Neuro Oncol Date: 2012-06-26 Impact factor: 12.300
Authors: Priscilla K Brastianos; Ganesh M Shankar; Corey M Gill; Amaro Taylor-Weiner; Naema Nayyar; David J Panka; Ryan J Sullivan; Dennie T Frederick; Malak Abedalthagafi; Pamela S Jones; Ian F Dunn; Brian V Nahed; Javier M Romero; David N Louis; Gad Getz; Daniel P Cahill; Sandro Santagata; William T Curry; Fred G Barker Journal: J Natl Cancer Inst Date: 2015-10-23 Impact factor: 13.506
Authors: Hermann L Müller; Maithé Tauber; Elizabeth A Lawson; Jale Özyurt; Brigitte Bison; Juan-Pedro Martinez-Barbera; Stephanie Puget; Thomas E Merchant; Hanneke M van Santen Journal: Nat Rev Dis Primers Date: 2022-04-21 Impact factor: 52.329